Výsledky vyhledávání - "Nora M. Fagan"

Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia

Autor: Nora M. Fagan, Maximilian Stahl, Amer M. Zeidan, Gautam Borthakur, Geoffrey L. Uy, Nikolai A. Podoltsev, Tillmann Taube, Hagop M. Kantarjian, Jorge E. Cortes, Sushmita Rajeswari

Publikováno v: International Journal of Hematology. 113:92-99

Polo-like kinase 1 (PLK1) regulates mitotic checkpoints and cell division. PLK1 overexpression is reported in numerous cancers, including acute myeloid leukemia (AML), and is associated with poor prognosis. Volasertib is a selective, potent cell-cycl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::334dfde0f3fa5b83fa13897878a7e163
https://doi.org/10.1007/s12185-020-02994-8

Zobrazit plný text záznamu

FC 049A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS

Autor: Nora M. Fagan, Sudha Visvanathan, Valerie Belsack, Rhona Recto, Jing Wu, Jürgen Steffgen, Richard Furie, Ivette Revollo, Kajohnsak Noppakun, David Jayne, Juanita Romero-Diaz, Steven J. Padula, Harold Michael Gomez, Hirofumi Amano

Publikováno v: Nephrology Dialysis Transplantation. 36

Background and Aims In patients (pts) with SLE, activation of the CD40–CD40L pathway results in stimulation and proliferation of B cells and other inflammatory cell types. The subsequent generation of autoantibodies and their deposition in the kidn

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6acd6fe3b18347dfba8a5db461d5552e
https://doi.org/10.1093/ndt/gfab140.001

Zobrazit plný text záznamu

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Autor: Nora M. Fagan, Audrey Koitka-Weber, Yuliya Lytvyn, Bruce A. Perkins, Nima Soleymanlou, Erik J.M. van Bommel, Jaap A. Joles, Daniël H. van Raalte, David Z.I. Cherney

Publikováno v: van Bommel, E J M, Lytvyn, Y, Perkins, B A, Soleymanlou, N, Fagan, N M, Koitka-Weber, A, Joles, J A, Cherney, D Z I & van Raalte, D H 2020, ' Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function ', Kidney International, vol. 97, no. 4, pp. 631-635 . https://doi.org/10.1016/j.kint.2019.12.021
Kidney International, 97(4), 631-635. Nature Publishing Group

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a095361c0f9e12a906b15c95348969f
https://research.vumc.nl/en/publications/054240d6-2d8a-4458-a79a-76a14052825e

Zobrazit plný text záznamu

POS0687 A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS

Autor: D. R. W. Jayne, R. Recto, Ivette Revollo, Jürgen Steffgen, Kajohnsak Noppakun, Jing Wu, Hirofumi Amano, Valerie Belsack, Richard Furie, Nora M. Fagan, H. M. Gomez, Juanita Romero-Diaz, Steven J. Padula, Sudha Visvanathan

Publikováno v: Annals of the Rheumatic Diseases. 80:589-590

Background:In patients with SLE, activation of the CD40–CD40L pathway results in stimulation and proliferation of B cells and other inflammatory cell types. The subsequent generation of autoantibodies and their deposition in the kidney, as well as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1b075a3da0042dc48ac5abb3151aeeab
https://doi.org/10.1136/annrheumdis-2021-eular.1401

Zobrazit plný text záznamu

Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease

Autor: Lee Canale, Danna Jennings, William Seiple, Mark Forrest Gordon, Richard B Rosen, Nora M. Fagan, Leona Borchert

Publikováno v: Parkinson's Disease
Parkinson's Disease, Vol 2016 (2016)

Background.Parkinson’s disease (PD) progressively affects dopaminergic neurotransmission and may affect retinal dopaminergic functions and structures.Objective.This 2-year randomized, open-label, parallel-group, flexible-dose study,NCT00144300, eva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f898689daa5de3a553a2c6cd44953dff
https://doi.org/10.1155/2016/8298503

Zobrazit plný text záznamu

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

Autor: Roger Mazze, Bruce A. Perkins, Nima Soleymanlou, Justin A. Lee, David Z.I. Cherney, Holly Tschirhart, Stefan Kaspers, Nora M. Fagan, Uli C. Broedl, Odd Erik Johansen, Hans-Juergen Woerle, Helen Partridge, Bernard Zinman

Publikováno v: PLoS ONE, Vol 10, Iss 11, p e0141085 (2015)
PLoS ONE

Background We recently reported improved glycemic control with reduced insulin dose in subjects with type 1 diabetes treated with the sodium glucose co-transporter-2 inhibitor empagliflozin. To further characterize the effects, we analyzed diurnal gl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e32796da7027d98c34dac8b004f02666
http://europepmc.org/articles/PMC4636141?pdf=render

Zobrazit plný text záznamu

One-Year Evaluation of the Safety and Efficacy of Ipratropium Bromide HFA and CFC Inhalation Aerosols in Patients with Chronic Obstructive Pulmonary Disease

Autor: Shari A. Brazinsky, Robert J. Lapidus, Theodore J. Witek, Nora M. Fagan, Mo Ghafouri, Laurence A. Weiss

Publikováno v: Clinical Drug Investigation. 23:181-191

Introduction: Ipratropium bromide (IB) is an established and effective first-line maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). A new IB metered-dose inhaler (MDI) using hydrofluoroalkane 134a propellant (IB HF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7af1f8cc489f35e86b3d242123f1a35c
https://doi.org/10.2165/00044011-200323030-00004

Zobrazit plný text záznamu

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial

Autor: Bruce A. Perkins, Stefan Kaspers, Nora M. Fagan, Helen Partridge, Odd Erik Johansen, Nima Soleymanlou, Hans-Juergen Woerle, David Z.I. Cherney, Holly Tschirhart, Uli C. Broedl, Bernard Zinman

Publikováno v: Diabetes care. 37(5)

OBJECTIVE Adjunctive-to-insulin therapy with sodium-glucose cotransporter 2 (SGLT2) inhibition may improve glycemic control in type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS We evaluated the glycemic efficacy and safety of empagliflozin 25 mg dai

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027143ae1ae75aac7f8681ba65dff4b0
https://pubmed.ncbi.nlm.nih.gov/24595630

Zobrazit plný text záznamu

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus

Autor: Bruce A. Perkins, Vesta Lai, David Z.I. Cherney, Nora M. Fagan, Uli C. Broedl, Nima Soleymanlou, Maria Maione, Alana Lee, Maximilian von Eynatten, Hans-Juergen Woerle, Odd Erik Johansen

Publikováno v: Circulation. 129(5)

Background— The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks’ sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects with ty

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d65ba474c713f40c0efa84afb264331
https://pubmed.ncbi.nlm.nih.gov/24334174

Zobrazit plný text záznamu

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

Autor: Ronnie Har, Hans-Juergen Woerle, Odd Erik Johansen, Nima Soleymanlou, Bruce A. Perkins, Maximilian von Eynatten, Uli C. Broedl, Nora M. Fagan, David Z.I. Cherney

Publikováno v: Cardiovascular Diabetology

Background Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial stiffness, and is an importan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92246c54ff084b74222b38c369e6cd16
https://doi.org/10.1186/1475-2840-13-28

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání